Chemotherapy

Antinausea drug will likely get approval in U.S.

Published in Biotech Business Week, March 31st, 2003

Merck and Co.'s experimental treatment for preventing nausea and vomiting in chemotherapy patients won key support from a group of government advisers, meaning the drug will likely be approved for sale in the United States.

The group of outside experts told the U.S. Food and Drug Administration (FDA) that Merck's Emend cut down vomiting and nauseous episodes better than standard available treatments.

Vomiting and nausea often plague patients on certain chemotherapies called highly emetogenic because they are known to be difficult to stomach.

FDA, which rarely goes against the advice of its expert panels, is expected to meet with...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2003-03-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry